Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Veracyte Inc
(NQ:
VCYT
)
20.80
-0.04 (-0.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Veracyte Inc
< Previous
1
2
3
4
5
6
Next >
New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
October 14, 2021
From
Veracyte, Inc.
Via
Business Wire
New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy
October 13, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
October 12, 2021
From
Veracyte, Inc.
Via
Business Wire
New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
October 11, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment
October 11, 2021
From
Veracyte, Inc.
Via
Business Wire
New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease
October 06, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy
September 14, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology
September 01, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
August 31, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year
August 23, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Completes Acquisition of HalioDx
August 03, 2021
From
Veracyte
Via
Business Wire
Veracyte Announces Second Quarter 2021 Financial Results
July 29, 2021
From
Veracyte, Inc.
Via
Business Wire
New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer
July 27, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
July 12, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
July 08, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion
July 08, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
July 01, 2021
From
Veracyte, Inc.
Via
Business Wire
New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
June 14, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
June 04, 2021
From
Veracyte, Inc.
Via
Business Wire
CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences
June 02, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Present at Upcoming Investor Conferences
June 02, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth
June 01, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Present at Upcoming Investor Conferences
May 26, 2021
From
Veracyte
Via
Business Wire
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples
May 26, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier
May 25, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
May 19, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Present at Upcoming Investor Conferences
May 18, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis
May 14, 2021
From
Veracyte
Via
Business Wire
Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy
May 14, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte, Inc. Announces CEO Succession Plan
May 10, 2021
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.